Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback